![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
LJ Olson, DG Lowe and JG Drewett
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee 53226, USA.
We report the production of a novel human natriuretic peptide receptor/guanylyl cyclase A (hNPR-A)-selective agonist ANP [G9T, R11S, G16R] (sANP). This agonist has similar affinity to ANP for hNPR-A and 1,000-10,000-fold reduced affinity for the human natriuretic peptide clearance receptor (hNPR-C). sANP was used to directly test the hypothesis that hNPR-A mediates the inhibitory effect of natriuretic peptides on aldosterone generation in a human zona glomerulosa cell line, H295R. Human type A natriuretic peptide and sANP (10(-11) to 10(- 6) M) resulted in concentration-dependent increases in cGMP levels and decreases in forskolin (100 nM)- and angiotensin II (5 nM)-induced aldosterone and pregnenolone production. These results revealed an inhibitory effect of both peptides on the agonist-stimulated conversion of cholesterol to pregnenolone (i.e., cytochrome P-450 cholesterol monooxygenase side-chain cleaving enzyme, EC 1.14.15.6). H295R cells also exhibited angiotensin II- and forskolin-evoked conversion of [3H]cortico-sterone to [3H]aldosterone (i.e., cytochrome P-450 steroid 11 beta-monooxygenase/aldosterone synthase, EC 1.14.15.4). Human type A natriuretic peptide and sANP (10(-7) M) inhibited the angiotensin II- stimulated late pathway but did not affect forskolin-facilitated conversion of corticosterone to aldosterone. Our results directly demonstrate inhibitory effects of hNPR-A-mediated signal transduction on cytochrome P-450 cholesterol monooxygenase side-chain cleaving enzyme and steroid 11 beta-monooxygenase/aldosterone synthase complex depending on the steroidogenic agonist used.
This article has been cited by other articles:
|
|
 |
|
  L. R. Potter, S. Abbey-Hosch, and D. M. Dickey Natriuretic Peptides, Their Receptors, and Cyclic Guanosine Monophosphate-Dependent Signaling Functions Endocr. Rev., February 1, 2006; 27(1): 47 - 72. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Airhart, Y.-F. Yang, C. T. Roberts Jr., and M. Silberbach Atrial Natriuretic Peptide Induces Natriuretic Peptide Receptor-cGMP-dependent Protein Kinase Interaction J. Biol. Chem., October 3, 2003; 278(40): 38693 - 38698. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Salemi, J. G. McDougall, K. J. Hardy, and E. M. Wintour Local inhibition of nitric oxide temporarily stimulates aldosterone secretion in conscious sheep in vivo Am J Physiol Endocrinol Metab, April 1, 2001; 280(4): E584 - E590. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Olson, B. Y. Ho, L. W. Cashdollar, and J. G. Drewett Functionally Active Catalytic Domain Is Essential for Guanylyl Cyclase-Linked Receptor Mediated Inhibition of Human Aldosterone Synthesis Mol. Pharmacol., November 1, 1998; 54(5): 761 - 769. [Abstract] [Full Text]
|
|
|
|
 |
|
 C. J. Hanke, J. G. Drewett, C. R. Myers, and W. B. Campbell Nitric Oxide Inhibits Aldosterone Synthesis by a Guanylyl Cyclase-Independent Effect Endocrinology, October 1, 1998; 139(10): 4053 - 4060. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. J. Olson, E. T. Knych Jr, T. C. Herzig, and J. G. Drewett Selective Guanylyl Cyclase Inhibitor Reverses Nitric Oxide-Induced Vasorelaxation Hypertension, January 1, 1997; 29(1): 254 - 261. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
